It appears you don't have support to open PDFs in this web browser. To view this file, Open with your PDF reader
Abstract
Abnormal trophoblast self-renewal and differentiation during early gestation is the major cause of miscarriage, yet the underlying regulatory mechanisms remain elusive. Here, we show that trophoblast specific deletion of Kat8, a MYST family histone acetyltransferase, leads to extraembryonic ectoderm abnormalities and embryonic lethality. Employing RNA-seq and CUT&Tag analyses on trophoblast stem cells (TSCs), we further discover that KAT8 regulates the transcriptional activation of the trophoblast stemness marker, CDX2, via acetylating H4K16. Remarkably, CDX2 overexpression partially rescues the defects arising from Kat8 knockout. Moreover, increasing H4K16ac via using deacetylase SIRT1 inhibitor, EX527, restores CDX2 levels and promoted placental development. Clinical analysis shows reduced KAT8, CDX2 and H4K16ac expression are associated with recurrent pregnancy loss (RPL). Trophoblast organoids derived from these patients exhibit impaired TSC self-renewal and growth, which are significantly ameliorated with EX527 treatment. These findings suggest the therapeutic potential of targeting the KAT8-H4K16ac-CDX2 axis for mitigating RPL, shedding light on early gestational abnormalities.
Embryo implantation failure is a leading cause of miscarriage, though the mechanisms underlying trophoblast defects are not well understood. Here they show that the histone acetyltransferase KAT8 is essential for proper activation of the trophoblast stemness gene CDX2, and that placental development can be partially rescued by inhibiting histone deacetylase activity.
You have requested "on-the-fly" machine translation of selected content from our databases. This functionality is provided solely for your convenience and is in no way intended to replace human translation. Show full disclaimer
Neither ProQuest nor its licensors make any representations or warranties with respect to the translations. The translations are automatically generated "AS IS" and "AS AVAILABLE" and are not retained in our systems. PROQUEST AND ITS LICENSORS SPECIFICALLY DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING WITHOUT LIMITATION, ANY WARRANTIES FOR AVAILABILITY, ACCURACY, TIMELINESS, COMPLETENESS, NON-INFRINGMENT, MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE. Your use of the translations is subject to all use restrictions contained in your Electronic Products License Agreement and by using the translation functionality you agree to forgo any and all claims against ProQuest or its licensors for your use of the translation functionality and any output derived there from. Hide full disclaimer
Details








1 The Third Affiliated Hospital of Guangzhou Medical University, Department of Obstetrics and Gynecology, Guangzhou, China (GRID:grid.417009.b) (ISNI:0000 0004 1758 4591); The Third Affiliated Hospital of Guangzhou Medical University, Guangdong Provincial Key Laboratory of Major Obstetric Diseases, Guangzhou, China (GRID:grid.417009.b) (ISNI:0000 0004 1758 4591); The Third Affiliated Hospital of Guangzhou Medical University, Guangdong Provincial Clinical Research Center for Obstetrics and Gynecology, Guangzhou, China (GRID:grid.417009.b) (ISNI:0000 0004 1758 4591); The Third Affiliated Hospital of Guangzhou Medical University, Guangdong-Hong Kong-Macao Great Bay Area Higher Education Joint Laboratory of Maternal-Fetal Medicine, Guangzhou, China (GRID:grid.417009.b) (ISNI:0000 0004 1758 4591)
2 Capital Medical University. Beijing Maternal and Child Health Care Hospital, Central Laboratory, Beijing Obstetrics and Gynecology Hospital, Beijing, China (GRID:grid.459697.0)
3 National Institute of Biological Sciences, Beijing, China (GRID:grid.410717.4) (ISNI:0000 0004 0644 5086); Tsinghua University, Tsinghua Institute of Multidisciplinary Biomedical Research, Beijing, China (GRID:grid.12527.33) (ISNI:0000 0001 0662 3178)
4 Mannheim Institute of Innate Immunosciences (MI3), Medical Faculty Mannheim, Heidelberg University, Institute of Transfusion Medicine and Immunology, Mannheim, Germany (GRID:grid.420674.3) (ISNI:0000 0001 0696 6322); German Red Cross Blood Service Baden-Württemberg-Hessen, Mannheim, Germany (GRID:grid.433743.4) (ISNI:0000 0001 1093 4868); National Research Tomsk State University, Laboratory of Translational Cellular and Molecular Biomedicine, Tomsk, Russia (GRID:grid.77602.34) (ISNI:0000 0001 1088 3909)
5 The First Affiliated Hospital of Xiamen University, School of Medicine, Xiamen University, Fujian Provincial Key Laboratory of Reproductive Health Research, Department of Obstetrics and Gynecology, Xiamen, China (GRID:grid.412625.6)